





I - Executive Summary

Enhance your detection



Executive summary - Key Investment Considerations

Why invest in Poly-Dtech?



Executive summary - Who we are

Built by two co-founders, Poly-Dtech is now managed by a seasoned team of experts, supported by Tier 1 board members & scientists

Joan Goetz
CEO - Co-Founder



PhD in Chemistry (Strasbourg / Hong Kong)
eMBA (Montpellier Business School)




Dr. Loïc Charbonnière
CSO - Co-Founder



PhD in Chemistry (Strasbourg)
Laboratory Director (IPHC / UDS / CNRS)



C-Level



COO
15+ years of experience at
Merck (Strategy)



Carole Poutriquet - CBO
20+ years in life sciences
product commercialization




**Fisher
Scientific**



PerkinElmer
precisely.

Business Development



Head of N.America Bus.Dev.
(Based in North America)
10+ years of experience in
Business Development

Quanterix
The Science of Precision Health



Strategic board



Cédric Chaffois



Tim Bernard



R&D



Dr. Susana Brun
Manager - Biology



Dr. Mohamadou Sy
Manager - Chemistry



Scientific board



Pr. Niko
Hildebrandt
Expert - FRET



Dr. Alexandre
Detappe
Cancer / Diagnostics



Scientific support



Pr. J.M. Lehn
Nobel prize in Chemistry
Expertise in TR-FRET
Technical support via his
foundation



Executive summary - What we do

We develop and produce immunoassay kits with unique characteristics, to improve the detection of biomarkers in the service of scientific research and medical diagnosis

Our core business relies on producing and selling immunoassay kits for biomarker detection...

Founded in 2019 and headquartered in **Strasbourg (France)**, we commercialize our in-house developed immunoassay kits as well as provide nanoparticle related services (custom coupling development, custom nanoparticle development, etc.) and assay related services

Kits

- Our immunoassay kits NoW-Dtech™ and Multi-Dtech are based on the TR-FRET technique (Time-Resolved Fluorescence Energy Transfer) and integrate our proprietary innovative nanoparticles Bright-Dtech™
- By combining FRET and our nanoparticles, our kits can be used for the detection and the quantification of specific proteins, biomolecules, peptides, cytokines, hormones or antibodies, present in serum, plasma or cell culture supernatant



Services

- We provide custom assay development services using our proprietary Bright-Dtech™ technology for several types of assays:
 - TR-FRET
 - TR-FRET multiplexing
 - ELISA
 - Lateral Flow
- We also provide nanoparticle related services such as custom coupling development and custom nanoparticles development

...helping the scientific community's R&D efforts and bound to serve the medical diagnosis ecosystem

Fluorescent immunoassays and multiplexing markets, i.e., biomarker tools & reagents

Usage	RUO ⁽¹⁾	In Vitro Diagnostic (IVD) <small>(to be covered in 2029+)</small>
Clients	<ul style="list-style-type: none"> Corporates (Pharma / Biotech) Academic R&D centers CROs⁽²⁾ 	<ul style="list-style-type: none"> Corporates (IVD) Laboratories Hospitals
Applications	<ul style="list-style-type: none"> Biomarker & target studies Screening & drug discovery 	<ul style="list-style-type: none"> Human diagnostic Animal health monitoring & disease surveillance Pathogen and contaminants detection (Food & Environment)
Sectors	<div>Human health</div> <div>Animal health <small>(to be covered in 2029+)</small></div> <div>Environmental <small>(to be covered in 2029+)</small></div> <div>Food quality <small>(to be covered in 2029+)</small></div>	
Market size	TAM: \$5.1bn (2024) with a CAGR of 9.6% (2024-2029) SAM: \$354m (2024) with a share of 6.9% TAM (2024)	


Executive summary - Our innovation

The biomarker tools & reagents market is experiencing evolving needs requiring players to adapt, however, substitute solutions include their own set of limitations, which are addressed by NoW-Dtech™ (vs. TR-FRET) & Multi-Dtech (vs. Multiplexing)


1 The ELISA immunoassay technique is the market's gold standard, but it is showcasing several limitations as the market evolves

- **ELISA** (enzyme-linked immunosorbent assay) tests have long been the **benchmark for immunoassays**, offering a reliable and well-established method based on measuring the activity of a **reporter enzyme**
- However, constantly **evolving research needs** are exposing this technique's **limitations**, giving way to other **potential substitutes**


ELISA limitations vs. market's evolving needs




Low sensitivity



Low assay range
(single-target)



Low throughput



Time consuming
(multiple steps)

3 ... however, they still lack in ease-of-use (complexity), costs and flexibility, leaving room for our optimal immunoassay kits, adapted to the market's requirements

How our immunoassay kits compare vs. ELISA, TR-FRET & Multiplexing

	Single-target assays			Multi-target assays	
	ELISA kits	TR-FRET kits	NoW-Dtech™	Multiplexing kits	Multi-Dtech
Time efficiency	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>
Sensitivity	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>
Ease-of-use	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>
# of targets	1	1	1	15+ (average)	2-12 ⁽¹⁾
Flexibility	<div><div></div></div> ⁽²⁾	<div><div></div></div> ⁽²⁾	n.a.	<div><div></div></div>	<div><div></div></div>
Cost-friendly	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>	<div><div></div></div>

2 Other solutions have emerged to address ELISA's restrictions...

Given these pain points, new techniques have emerged as substitutes to ELISA tests, but showcase their own set of limitations:

- TR-FRET**: An advanced principle that combines time-resolved fluorescence (TRF) with Fluorescence Resonance Energy Transfer (FRET) to provide sensitive and specific measurements. The TR-FRET assay principle is based on the energy transfer **between two fluorophores**, a donor and an acceptor, when they are in close proximity

TR-FRET (single-target assay), compared with ELISA (single-target assay)

Pros of TR-FRET vs. ELISA	Cons of TR-FRET vs. ELISA
➤ Quicker results / higher throughput	➤ Additional complexity
➤ Increased sensitivity / precision	➤ Higher unit cost
	➤ Requires a small investment

- Multiplexing**: This method uses **fluorescent color-coded bead sets** that are coated with antibodies, each specific to an analyte of interest. The detection of both the capture bead and antibody allows for simultaneous measurement of multiple targets from a single sample

Multiplexing (multi-target assay), compared with ELISA (single-target assay)

Pros of Multiplexing vs. ELISA	Cons of Multiplexing vs. ELISA
➤ Increased sensitivity / precision	➤ Significant complexity
➤ Higher assay range (15+ targets on average)	➤ Higher unit cost
	➤ Requires significant investment

Source(s): Revvity; Note(s): (1) 12 simultaneous targets (2029 objective); (2) Multiple single assays tests in case of multi-target testing

Executive summary - Market & adoption

Our two innovations solve ELISA's low sensitivity, assay range, throughput and time consumption pain points, all while fixing the current substitutes' problems linked to ease-of-use and affordability, ideally positioning ourselves for fast market adoption

1

Our immunoassay kits are better than our competitors' due to our two main innovations

Bright-Dtech™

Our proprietary fluorescent nanoparticles make biomarker detection **easier** and **more affordable** due to their unique features, showcasing **strong brightness, long emission lifetime & resilient photo-stability**



Multi TR-FRET technique

Classic multiplexing comes with a strong degree of **complexity** and **requires a specific set of expertise & equipment**

Our multiplexing technique based on TR-FRET allows our clients to **seamlessly** test several biomarkers with **no additional investments**

Game changer



2

Our innovations are at different stages of maturity, but have already showcased their technical & commercial Proofs Of Concept

I - Bright-Dtech™

- Our proprietary nanoparticles technology is fully developed
- Next stages of R&D entail improving the technology for 12-target multiplexing and other analysis techniques



II - Multi TR-FRET technique

- Our TR-FRET based multiplexing technique currently allows the simultaneous testing of 2 biomarkers
- Next stages of R&D entail reaching 3 to 4 biomarkers by end of 2025, and up to 12 biomarkers by end of 2029

We're ideally positioned to become the TR-FRET multiplexing pioneer, addressing historical & evolving testing needs

- Current client & partner feedback confirms the market is open & ready to adopt our kits, highlighting our kits' ease-of-use, affordability and reliability as their main choice criteria
- We keep intensifying our research to further develop our solutions, while market feedback shows that clients' multiplexing sweet spot is around 3 to 4 biomarkers, making us ready for mass market commercialization starting H2 2026

World's only provider of TR-FRET multiplexing kits



4

Our immunoassay kits are designed for specific biomarkers, with different stages of coverage depending on the therapeutic area

Current biomarker focus

- ✓ **Antibodies:** 5/7 biomarkers (7/7 in 2025)
- ✓ **Cytokines / inflammatory:** 3/52 of biomarkers (52/52 in 2027)
- ✓ **Oncology:** 2/42 of biomarkers (42/42 in 2027)
- ✓ **Cell signaling:** 0/50 of biomarkers (50/50 in 2028)

Biomarker coverage pipeline


- ❑ **Neurosciences:** 0/30 of biomarkers (30/30 in 2029)
- ❑ **Cardiovascular:** 0/20 of biomarkers (20/20 in 2029)
- ❑ **Virology / bacteria:** 2/16 of biomarkers (16/16 in 2029)
- ❑ **Metabolic / endocrinology:** 0/28 of biomarkers (28/28 in 2029)

3

Executive summary - Fundraising & Use of proceeds

We invite you to join us on the immunoassay kits' evolution journey to allow us to reach our full potential in 2029. Investing in Poly-Dtech represents a rare opportunity given the different exit possibilities in a Life Sciences Tools M&A market that's gaining momentum due to (i) corporates preferring to acquire innovation rather than develop it in-house & (ii) an increasing appetite from PE funds towards this sector

Poly-Dtech ownership structure



Business Plan⁽¹⁾ & use of proceeds

P&L - €k	2025	2026	2027	2028	2029	2030	2033	
Net sales	102	607	1,677	4,270	11,808	19,497	27,200	c. 228% CAGR% 2025-2029
EBITDA	(64)	(1,139)	(1,638)	(1,038)	2,862			c. 24% 2029 EBITDA margin
Net income	(165)	(1,359)	(1,868)	(1,368)	2,493			c. 21% 2029 Net income margin

Cash Flows - €k	2025	2026	2027	2028	2029
From Operations	(59)	(1,244)	(1,746)	(1,352)	1,694
From Investing	(186)	(560)	(673)	(863)	(803)
From Financing	105	(99)	(106)	(122)	(102)
Total	(140)	(1,903)	(2,525)	(2,336)	788

Based on clients acquired by 2029, the 2029 €12m net sales will progressively amount to €27m in 2033, as 2026-2029 cohorts fully achieve their normative kit purchasing behavior potential

- Our 2025-2029 Business Plan includes an ambitious roadmap to reach c. €12m in net sales in 2029 and become profitable, however, this plans requires a €7.5m financing to cover our negative cash situation in 2025-2028. The €12m in net sales in 2029 isn't representative of our full commercial potential, as clients (notably pharma) require a 12-month testing phase, with a progressively increasing kit purchasing behavior before stabilizing to their normative level

- In order to achieve our main objectives in 2029, our expenses and investments will be focused on the following

- R&D (c. 21%)
- Production scale up (c. 23%)
- Marketing & Sales (c. 25%)
- Expansion support (c. 31%)

Poly-Dtech, vision 2029



Strengthened portfolio & client coverage
(addressing other therapeutic areas & sectors with enhanced multiplexing capacities)



Complete geographic coverage
(with our own office in the USA)



Structured team with 43 FTEs
(to help execute our 2025-2029 business plan)